A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.
After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.
New research analyzing over 72,000 pregnant COVID-19 patients reveals they face a significantly reduced risk of developing long-term symptoms compared to nonpregnant women, with key risk factors identified across both cohorts.